Clinical trial in progress: Pivotal study of VB-111 combined with paclitaxel versus paclitaxel for treatment of platinum-resistant ovarian cancer (OVAL, VB-111-701/GOG-3018).

Rebecca C. Arend,Bradley J. Monk,Robert A. Burger,Thomas J. Herzog,Jonathan A. Ledermann,Kathleen N. Moore,Angeles Alvarez Secord,Roni Shapira,Krishnansu S. Tewari,Marilyn Huang,Amnon Amit,Tamar Rachmilewitz Minei,Dror Harats,Richard T. Penson

Clinical trial in progress: Pivotal study of VB-111 combined with paclitaxel versus paclitaxel for treatment of platinum-resistant ovarian cancer (OVAL, VB-111-701/GOG-3018).

2020

Rebecca C. Arend
Bradley J. Monk
Robert A. Burger
Thomas J. Herzog
Jonathan A. Ledermann
Kathleen N. Moore
Angeles Alvarez Secord
Roni Shapira
Krishnansu S. Tewari
Marilyn Huang
Amnon Amit
Tamar Rachmilewitz Minei
Dror Harats
Richard T. Penson

TPS6097Background: Ofranergene obadenovec (VB-111) is a targeted anti-cancer gene therapy with a dual mechanism: a broad antiangiogenic effect and induction of a tumor directed viral immune respons...

Keywords:

Clinical trial
platinum resistant
Paclitaxel
Oncology
Internal medicine
Medicine
Pathology
Ovarian cancer

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations